Abstract
Diabetes is a proinflammatory state and inflammation is crucial in the genesis of vascular complications. While there are many anti-inflammatory strategies, most of which have been shown to reduce inflammation in diabetes, there is sparse data on reduction in cardiovascular events (CVEs). To date, the only anti-inflammatory strategies that have been shown to reduce CVE in diabetes include statins, angiotensin receptor blockers, metformin, and pioglitazone. We also discuss the role of novel emerging therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 121-123 |
Number of pages | 3 |
Journal | Clinical Pharmacology and Therapeutics |
Volume | 98 |
Issue number | 2 |
DOIs | |
State | Published - Aug 1 2015 |
ASJC Scopus subject areas
- Medicine(all)